<aside> 💡

Revolutionizing the future of neurodegenerative disease treatment by unlocking the potential of plant-based protein folding and degradation mechanisms, offering pioneering therapies for rare and untreatable age-related protein aggregation disorders like Huntington’s disease

</aside>

Core Team

Organization and Network

Executive summary

• We are pioneering a therapeutic platform targeting toxic protein aggregation clusters in Huntington's disease (HD) and other polyglutamine disorders, impacting millions globally. Our approach uses a groundbreaking plant-derived protein mechanism that blocks polyglutamine aggregation in in vitro HD models.
• We identified a fundamental mechanism that regulates and prevents protein aggregation in both plants and human cells. Our platform rewires plant protein aggregation mechanisms to generate novel therapeutic candidates for HD and other disorders.
• Unlike conventional gene silencing strategies, we directly block the formation of pathogenic huntingtin protein aggregates without interfering with the protein's natural role.
• Key achievements:
  • Patent application submitted
  • Published in Nature Aging
  • Secured €0.7M for preclinical validation
• Our provisional patent describes a plant-derived therapeutic candidate with freedom to operate in the HD therapeutic market. We plan to extend applications to other neurodegenerative disorders.
• Our technology could potentially treat multiple age-related neurodegenerative disorders involving protein aggregation.
• Our team includes pharmaceutical and scientific experts providing support throughout preclinical and clinical phases.

Explanatory Video: Project Overview